1. Home
  2. MMYT vs NAMS Comparison

MMYT vs NAMS Comparison

Compare MMYT & NAMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MakeMyTrip Limited

MMYT

MakeMyTrip Limited

HOLD

Current Price

$46.81

Market Cap

4.2B

ML Signal

HOLD

Logo NewAmsterdam Pharma Company N.V.

NAMS

NewAmsterdam Pharma Company N.V.

HOLD

Current Price

$28.12

Market Cap

3.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MMYT
NAMS
Founded
2000
2019
Country
India
Netherlands
Employees
N/A
100
Industry
Transportation Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.2B
3.5B
IPO Year
2010
N/A

Fundamental Metrics

Financial Performance
Metric
MMYT
NAMS
Price
$46.81
$28.12
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
8
Target Price
$101.00
$46.75
AVG Volume (30 Days)
1.5M
887.3K
Earning Date
05-20-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$16.83
$17.96
Revenue Next Year
$17.24
$540.65
P/E Ratio
$107.67
N/A
Revenue Growth
N/A
N/A
52 Week Low
$32.67
$16.79
52 Week High
$113.85
$42.00

Technical Indicators

Market Signals
Indicator
MMYT
NAMS
Relative Strength Index (RSI) 53.30 35.47
Support Level $32.67 $23.48
Resistance Level $51.39 $37.25
Average True Range (ATR) 1.92 1.83
MACD 0.60 -0.64
Stochastic Oscillator 60.00 3.94

Price Performance

Historical Comparison
MMYT
NAMS

About MMYT MakeMyTrip Limited

MakeMyTrip Ltd is an online travel company, which provides online booking solutions for day-to-day travel needs. The company's operating segment includes Air ticketing; Hotels and packages; Bus ticketing and Others. It generates maximum revenue from the Hotels and packages segment. The Hotels and packages segments include internet-based platforms, call-centers, and branch offices, which provide holiday packages and hotel reservations. Its Air ticketing segment includes internet-based platforms, provides the facility to book domestic and international air tickets. Geographically, it derives a majority of revenue from India and also has a presence in the United States; South East Asia; Europe, and other countries.

About NAMS NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Share on Social Networks: